A new vaccine to improve tuberculosis prevention
Official title: A novel c-di-AMP-based recombinant BCG vaccine
Funded at Albany Medical College · NIH-10783087 · Data updated 2026-11-12
This study is looking to create a better vaccine for tuberculosis (TB) by using a special ingredient that helps boost the immune system, aiming to offer stronger protection for people who are at risk of getting TB.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albany Medical College NIH-funded |
| Lab location | 1 site (Albany, United States) |
| Project start | February 9, 2023 |
| Project end | January 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $203,750 |
| NIH project number | 5R21AI169111-02 |
| Project ID | NIH-10783087 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at high risk of tuberculosis infection, including those in endemic regions or with compromised immune systems.
✕Less likely to help
Patients who are not at risk for tuberculosis or those who have already been vaccinated with BCG may not benefit from this research.
What this research studies
This research aims to develop a more effective vaccine for tuberculosis (TB) by utilizing a novel recombinant Bacillus Calmette-Guérin (BCG) vaccine that incorporates cyclic di-AMP (c-di-AMP), a bacterial signaling molecule. The study investigates how enhancing the immune response through c-di-AMP can improve the vaccine's effectiveness against TB. By understanding the biological differences between the TB-causing bacteria and the current BCG vaccine, the researchers hope to create a vaccine that provides better protection for individuals at risk of TB.
Why it matters
Potential benefit: If successful, this research could lead to a more effective TB vaccine, significantly reducing the incidence of the disease.
How similar studies have gone: Other research has shown promise in using novel adjuvants like c-di-AMP to enhance vaccine efficacy, indicating a potential for success in this approach.
Where this research is happening
-
Albany Medical College
Albany, United States Active
Researchers
- Principal investigator: Bai, Guangchun — Albany Medical College
- Study coordinator: Bai, Guangchun
Related research
Other NIH-funded projects on the same topics.
-
Endothelial inflammation memory after sepsis and pneumonia
A scientist is studying how blood vessel cells “remember” sepsis and why survivors get worse when they catch pneumonia, with the goal of finding better ways to reduce organ damage.
-
How common gut bacteria may stop C. difficile from making spores
This project looks at whether common gut bacteria called enterococci can stop C. difficile from making hardy spores that spread infection, which could help people prone to C. difficile infections.
-
Kiss1 neurons in brain regions and how they influence reproduction
A small NIH-funded project looks at how specific brain cells (Kiss1 neurons) affect reproductive hormones in adults.
-
Endothelial genes linked to Alzheimer's progression in male and female brains
Aims to find blood vessel gene targets that change as Alzheimer's progresses, in both men and women, using mouse models to mirror human disease.
-
How tumor stiffness and tissue environment affect HER2 antibody therapy
This project studies how the physical environment inside HER2-positive tumors affects how well HER2-targeting antibodies can reach and engage their target in patients.
-
KCTD11-related CMT neuropathy: uncovering how it damages nerves
We are studying a genetic form of Charcot–Marie–Tooth disease to understand what goes wrong in nerves and support future treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.